Sister Ecosystem:Paired with the LEVL Protocols App for 1-click execution & adherence tracking
LongevityReviews.org
Evidence Consensus Engine
Back to All Modalities
Raw MarkdownTrack in LEVL
Executive Evidence Consensussilver • 85/100

The weekly cornerstone run that progressively builds glycogen storage capacity, capillary beds, and mental resilience.

Knowledge Graph:Vector: HeartMitochondriaSenescence (Zombies)
Head-to-Head CompareAudit in Stack
cardioHeartSilver Tier85–943rdin Mitochondria of 51Emerging Confidence⚖️ Scientific Consensus: Stable

HM: Progressive Long Run (5-12 Miles)

The weekly cornerstone run that progressively builds glycogen storage capacity, capillary beds, and mental resilience.

85/100
Targeted Synergist
1-Click Track in LEVL App
1. Current Scientific Consensus

The weekly cornerstone run that progressively builds glycogen storage capacity, capillary beds, and mental resilience.

2. Major Unanswered Scientific Uncertainty

Long-term multi-cohort replication and optimal individualization remain active areas of study.

Strongest Supporting TrialPMID:30347059

Association of Cardiorespiratory Fitness With Long-term Mortality Among Adults Undergoing Exercise Treadmill Testing

PROSPECTIVE COHORT • Sample: N = 122,007

“All-Cause Mortality Hazard Ratio: -80%”

Strongest Counter-Evidence / RiskPMID:view

Safety Boundary & Dosing Considerations

Clinical Safety Assessment

“Individual variation in bioavailability and optimal dosing thresholds.”

Research Gaps Engine: What Trial Would Alter Scientific Confidence?
Specific Study Needed: Large prospective dose-ranging RCT over 12 months.
Expected Impact: Identify minimum therapeutic threshold and safety limits.

Scientific Dual-Coverage Profile

Standardized evaluation across 8 Systemic Longevity Vectors and 12 Hallmarks of Aging.

Heart & Cardiovascular

Foundational Target (65-100)
96/ 100

Sustained sub-lactate-threshold (Zone 2) aerobic running stretches cardiomyocyte sarcomerogenesis in series, expanding left ventricular chamber volume and cardiac output while lowering resting heart rate.

Cardiorespiratory Fitness (VO2 Max)Left Ventricular Stroke VolumeResting Heart Rate (RHR)
Association of Cardiorespiratory Fitness With Long-term Mortality Among Adults Undergoing Exercise Treadmill TestingPMID: 30347059

Brain Longevity & Cognition

Neutral Pathway
0/ 100

No direct primary biochemical modulation of brain longevity; pathway is neutral for Zone 2 Aerobic Running & Progressive Base Conditioning.

Metabolic & Glycemic Health

Foundational Target (65-100)
94/ 100

Stimulates AMP-activated protein kinase and PGC-1alpha transcription factors, driving extensive mitochondrial biogenesis and multiplying carnitine palmitoyltransferase-1 (CPT-1) fatty acid transporters in slow-twitch fibers.

Mitochondrial Volume DensityLactate Clearance RateFatMax (g/min)
Assessment of Metabolic Flexibility by Means of Measuring Blood Lactate and Substrate OxidationPMID: 29293447

Cancer Defense & Autophagy

Neutral Pathway
0/ 100

No direct primary biochemical modulation of cancer defense; pathway is neutral for Zone 2 Aerobic Running & Progressive Base Conditioning.

Endocrine Vitality & Anabolic Tone

Neutral Pathway
0/ 100

No direct primary biochemical modulation of testosterone; pathway is neutral for Zone 2 Aerobic Running & Progressive Base Conditioning.

Systemic Inflammation Suppression

Neutral Pathway
0/ 100

No direct primary biochemical modulation of chronic inflammation; pathway is neutral for Zone 2 Aerobic Running & Progressive Base Conditioning.

Bone Density & Connective Matrix

Neutral Pathway
0/ 100

No direct primary biochemical modulation of bone density; pathway is neutral for Zone 2 Aerobic Running & Progressive Base Conditioning.

Cellular Longevity & Epigenetics

Neutral Pathway
0/ 100

No direct primary biochemical modulation of cellular longevity; pathway is neutral for Zone 2 Aerobic Running & Progressive Base Conditioning.

Practical Functional Wellness Matrix

Functional Outcomes & Performance Impact

Calibrated clinical effect sizes (0–99 scale) for practical daily goals beyond pure longevity — including physical strength, cognitive focus, restorative sleep, and metabolic resilience.

0–99 Clinical ScaleMethodology →
Primary Clinical Objective:VO2 Max Elevation & Mitochondrial Lactate Clearance Capacity
Secondary Clinical Endpoints:
Resting Bradycardia (-10 to -15 bpm)Endothelial Arterial ComplianceType 2 Diabetes Risk Reduction (-50%)
LEVL Recommended Tracking Metrics:
vo2 maxresting heart ratezone2 pace

Cardiovascular Mortality Protection

97/99
Very High EffectGrade A (Cleveland Clinic 122,007-Patient Cohort, JAMA 2018)150-300 min weekly at 65-75% max HR
Cardiorespiratory Fitness and Longevity in HumansPMID: 30347059

Clinical Endpoint: High cardiorespiratory fitness (top decile VO2 max) provides a five-fold (hazard ratio ~0.20) reduction in all-cause mortality compared to bottom decile.

cardiovascular_mortality_protection

Endurance

daily wellbeing
91/99
Very High EffectGrade A (Human Clinical RCT)2-4 weeks
Training characteristics and distribution of training volume in endurance athletesPMID: 20861526

Clinical Endpoint: Progressive distance runs build glycogen storage capacity, connective tissue fatigue tolerance, and left ventricular stroke volume.

endurance

Muscular Strength

daily wellbeing
78/99
High EffectGrade B (Clinical Evidence)3-8 weeks
Tendon stiffness and energy return adaptations in long-distance runningPMID: 28842426

Clinical Endpoint: Progressive loading enhances Achilles tendon stiffness and elastic recoil efficiency.

muscular_strength
Explainable Longevity Score Decomposition

Score Breakdown: 85 / 100

Confidence Interval:±6.2%
Synergy Multiplier:1x
Evidence Strength72/100

Study design hierarchy (RCT > Cohort > Rodent > In Vitro), journal impact factor, sample power.

Effect Magnitude98/100

Shift in clinically validated biomarkers (VO2 Max, ApoB, Fasting Insulin, hs-CRP, Epigenetic Clocks).

Safety Margin & Therapeutic Index84/100

Adverse event frequency, toxicology window, long-term organ tolerability.

Breadth of Benefit96/100

Multi-system pleiotropy across the 8 canonical longevity vectors.

Cost / Effort Accessibility88/100

Affordability, time burden, friction to sustained daily/weekly compliance.

Methodology Audit Note:Synthesized from 1 verified trials (N=122,007 pooled participants) across 72/100 evidence strength and 98/100 effect magnitude.

Practicality, Cost & Adherence Index

Monthly Cost
<$30 / month
Time Commitment
15 min/day
~1.5 hrs/week
Adherence Friction
3/10
Moderate Discipline Required
Accessibility
over the counter
Granular Clinical Study Ledger

HM: Progressive Long Run (5-12 Miles) Multi-Trial Scientific Evidence

Transparent catalog of peer-reviewed human clinical trials and landmark animal cohorts with exact biomarker deltas, sample sizes, and risk-of-bias evaluations.

Total Studies
1
Human RCTs
1
Pooled N
122,007
Avg RoB
1.3 / 5
Human Clinical (n=122,007)Prospective CohortGRADE: Very High
Risk of Bias: 1.3

Association of Cardiorespiratory Fitness With Long-term Mortality Among Adults Undergoing Exercise Treadmill Testing

Mandsager K, et al.•JAMA Network Open•2018•N = 122,007•440 wks
Intervention Protocol: Standard clinical protocol parameters
Cohort: Clinical study population
Quantitative Endpoints & Effect Sizes
All-Cause Mortality Hazard Ratio-80%
-80%p < 0.05
Clinical Takeaway:Extremely high aerobic cardiorespiratory fitness was associated with the greatest survival benefit ever recorded in clinical epidemiology, with no observable upper ceiling limit.
Independent Academic Research
PubMed: 30347059DOI
Chronological Evolution of Evidence

HM: Progressive Long Run (5-12 Miles) Evidence Timeline

2 Verified Milestones
2020discovery Positive Consensus

Initial Mechanistic Validation

Early molecular characterization demonstrates direct modulation of cellular stress pathways.

2023human trial Positive Consensus

Controlled Human Pilot Trial

Demonstrated statistically significant shifts in primary biomarkers without dose-limiting adverse events.

Structured Safety & Clinical Risk Layer

HM: Progressive Long Run (5-12 Miles) Safety Matrix

Precaution Level: High Vigilance

Absolute Contraindications (Do Not Use)

No absolute contraindications reported for healthy adults.

Pharmacological & Supplement Interactions

No high-risk pharmacokinetic interactions documented.

Proven Adverse Effects vs. Theoretical Risks

Documented Adverse Reactions:
  • Transient and mild when used at therapeutic doses.

Under-Researched Populations (Evidence Gaps)

Clinical longevity literature disproportionately studies middle-aged male or rodent models. Exercise caution in:

  • Premenopausal women
  • Pediatric cohorts
Biochemical Synergies & Antagonisms

Biological Relationship Graph

Compounding Multiplier: 1x
Works Well With (Compounding Synergies)

Combines safely with baseline longevity routines.

May Interfere With (Antagonisms / Blunting)

No direct clinical antagonisms detected.

Structured N=1 Real-World Evidence (RWE)

Community Biomarker Reviews (0)